Graft-versus-myeloma

Bone Marrow Transplantation

Volumn 22, Issue 9, 1998, Pages 835-843

  Mehta, J ^a   Singhal, S ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Allogeneic transplantation; Donor leukocyte infusion; Graft versus host disease; Graft versus myeloma; Immunotherapy; Interferon

Indexed keywords

ALPHA INTERFERON; CYCLOSPORIN; GANCICLOVIR; INTERLEUKIN 2; PREDNISONE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; GRAFT VERSUS MYELOMA EFFECT; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0031796809     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701459     Document Type: Article

References (67)

1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. New Engl J Med 1996; 335: 91-97.
2. Singhal S, Mehta J, Barlogie B. Advances in the treatment of multiple myeloma. Curr Opin Hematol 1997; 4: 291-297.
3. Mehta J, Powles R. Peripheral blood stem cell transplants and autotransplants. In: Whittaker JA, Holmes JA (eds). Leukaemia and Related Disorders. Blackwell: Oxford. 1998, pp 455-481.
4. Singhal S, Mehta J, Jagannath S, Barlogie B. Hematopoietic stem cell transplantation for myeloma. In: Foley JF, Vose JM, Armitage JO (eds). Current Therapy in Cancer, 2nd edn. WB Saunders: Philadelphia, 1998 (in press).
5. Bensinger WI, Demirer T, Buckner CD et al Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant 1996; 18: 527-531.
6. Gahrton G, Svensson H, Björkstrand B et al. Syngeneic bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1997; 19 (Suppl. 1): S88.
7. Seiden MV, Schlossman R, Andersen J et al. Monoclonal anti- body-purged bone marrow transplantation therapy for multiple myeloma. Leuk Lymphoma 1995; 17: 87-93.
8. Bensinger WI, Buckner CD. Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787-2793.
9. Björkstrand B, Ljungman P. Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective casematched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
10. Mehta J, Ayers D, Mattox S et al. Allogeneic bone marrow transplantation in multiple myeloma: single-center experience of 97 patients. Blood 1997; 90 (Suppl. 1): 225a.
11. Mehta J, Tricot G, Jagannath S et al. Salavage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887-892.
12. Bird JM, Russell NH, Samson D. Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant 1993; 12, 651-654.
13. Russell NH, Miflin G, Stainer C et al. Allogeneic bone marrow transplant for multiple myeloma. Blood 1997; 89: 2610-2611.
14. Kulkarni S, Powles R, Treleaven J et al. Allogeneic bone marrow transplantation for multiple myeloma. Blood 1997; 90 (Suppl. 1): 389b.
15. Mehta J. Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leuk Lymphoma 1993; 10: 427-432.
16. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
17. Or R, Mehta J, Naparstek E et al. Successful T cell-depleted allogeneic bone marrow transplantation in a child with recurrent multiple extramedullary plasmacytomas. Bone Marrow Transplant 1992; 10: 381-382.
18. Pavord S, Sivakumaran M, Durrant S, Chapman C. The role of alpha interferon in the pathogenesis of GVHD. Bone Marrow Transplant 1992; 10: 477.
19. Kolb HJ, Mittermüller J, Hertenstein H et al. Adoptive immunotherapy in human and canine chimeras - the role of interferon alfa. EBMT Chronic Leukemia Working Party. Semin Hematol 1993; 30 (Suppl. 3): 37-39.
20. Collins RH Jr, Pineiro LA, Nemunaitis JJ et al. Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. Transfusion 1995; 35: 891-898.
21. Verdonck LF, Lokhorst HM, Dekker AW et al. Graft-versus-myeloma effect in two cases. Lancet 1996; 347: 800-801.
22. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.
23. Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-1198.
24. Tricot G, Munshi N, Vesole D et al. Graft versus myeloma effect: risks and benefits. In: Dicke KA, Keating A (eds). Autologous Marrow and Blood Transplantation: Proceedings of the Eighth International Symposium. Arlington, Texas. Carden Jennings: Charlottesville, 1997, pp 225-232.
25. Aschan J, Lönnqvist B, Ringdén O et al. Graft-versus-myeloma effect. Lancet 1996; 348: 346.
26. Forsyth C, Nelson M, Popp H et al. Autologous red cell recovery and relapse of multiple myeloma after bone marrow transplantation: is this a graft-versus-myeloma effect? Bone Marrow Transplant 1996; 17: 457-459.
27. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leuko- cyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
28. Bertz H, Burger JA, Kunzmann R et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997; 11: 281-283.
29. Orsini E, Alyea EP, Schlossman R et al. Expansion of preexisting clonal populations following donor lymphocyte infusion for relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90 (Suppl. 1): 549a.
30. Glass B, Majolino I, Dreger P et al. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation. Bone Marrow Transplant 1997; 20: 533-541.
31. Zomas A, Stefanoudaki K, Fisfis M et al. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas. Bone Marrow Transplant 1998; 21: 1163-1165.
32. Abraham R, Szer J, Bardy P, Grigg A. Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants. Bone Marrow Transplant 1997; 20: 773-777.
33. Slavin S, Or R, Naparstek E et al. Cellular mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 1988; 72 (Suppl. 1): 407a.
34. Mehta J, Powles R, Singhal S et al. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996; 17: 371-375.
35. Mehta J, Powles R, Treleaven J et al. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant 1997; 20: 129-135.
36. Singhal S, Powles R, Kulkarni S et al. Immunotherapy of acute leukemia relapsing after allogeneic transplantation: the inseparability of GVHD and graft-vs-leukemia. and the problem of extramedullary relapse. Blood 1997; 90 (Suppl. 1): 547a.
37. Mehta J. The graft-versus-myeloma effect. In: Barrett AJ, Jiang YZ (eds). The Graft Versus Leukemia Effect in Allogeneic Stem Cell Transplantation. Marcel Dekker: New York, 1998 (in press).
38. Singhal S, Powles R, Treleaven J, Mehta J, Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferonα2b, Bone Marrow Transplant 1997; 19: 1151-1153.
39. Munshi NC, Govindarajan R, Drake R et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997; 89: 1334-1340.
40. Munshi NC, Tricot G, Jagannath S et al. Clinical results of thymidine kinase (TK) gene transduced donor lymphocyte infusion following allogeneic transplantation in myeloma. Blood 1997: 90 (Suppl. 1): 111a.
41. Singhal S, Mehta J, Powles R et al. Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 777-781.
42. Chang J, Powles R, Singhal S et al. Foscarnet therapy for cytomegalovirus infection after allogeneic bone marrow transplantation. Clin Infect Dis 1996; 22: 583-584.
43. Mehta J, Powles R, Singhal S et al. Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation. Leuk Lymphoma 1997; 26: 83-88.
44. Jarque I, Palau J, Sanz GF et al. Delayed complete response after allogeneic bone marrow transplantation in chronic lymphocytic leukemia. Blood 1993; 82: 1036-1038.
45. Singhal S, Powles R, Milan S et al. Clearance of paraprotein after autografting for multiple myeloma. Bone Marrow Transplant 1995; 16: 537-540.
46. Christiansen FT, Witt CS, Dawkins RL. Questions in marrow matching: the implications of ancestral haplotypes for routine practice. Bone Marrow Transplant 1991; 8: 83-86.
47. Békássy AN, Hermans J, Gorin NC, Gratwohl A. Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996; 17: 801-808.
48. Ashmun RA, Look AT. Metalloprotease activity of CD 13/aminopeptidase N on the surface of human myeloid cells. Blood 1990; 75: 462-469.
49. Vahdat L, Maslak P, Miller WH Jr et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis. low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-3849.
50. Ohsaka A, Sato N, Imai Y et al. Multiple gastric involvement by myeloid antigen CD13-positive non-secretory plasma cell leukaemia. Br J Haematol 1996; 92: 134-136.
51. Powles R, Singhal S, Treleaven J et al. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery after transplantation. Blood 1998; 91: 3481-3486.
52. Naparstek E, Or R, Nagler A et al. T cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506-515.
53. Samson D, Volin L, Schanz U et al. Feasibility and toxicity of interferon maintenance therapy after allogeneic BMT for multiple myeloma: a pilot study of the EBMT. Bone Marrow Transplant 1996; 17: 759-762.
54. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T cell-depleted allogeneic bone marrow transplantation. Blood 1994; 84: 964-971.
55. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016-1020.
56. Kwak LW, Pennington R, Longo DL. Active immunization of murine allogeneic bone marrow transplant donors with B cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood 1996; 87: 3053-3060.
57. Giralt S, Cohen A, Mehra R et al. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning. Blood 1997; 90 (Suppl. 1): 417a.
58. Slavin S, Nagler A, Naparstek E et al. Non-mycloablative stem cell transplantation and cell therapy as an alternative to conventional allogeneic bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91; 756-763.
59. Singhal S, Mehta J, Hood S et al. Third transplants for myeloma relapsing after two prior autografts. Blood 1997; 90 (Suppl. 1 ): 547a.
60. Porter DL, Connors JM, Doyle B et al. Donor leukocyte infusions as primary allogeneic adoptive immunotherapy for patients with malignancies. Blood 1997; 90 (Suppl. 1): 549a.
61. Mehta J, Powles R. Singhal S et al. Outcome of autologous rescue after failed engraftment of allogeneic marrow. Bone Marrow Transplant 1996; 17: 213-217.
62. Mehta J, Singhal S. Graft failure: diagnosis and management. In: Barrett J. Treleaven J (eds). The Clinical Practice of Stem Cell Transplantation. Isis: Oxford, 1998. pp 645-658.
63. Singhal S, Vourka-Karussis U, Mehta J et al. Failure of cyelosporine to induce graft-vs-host disease or graft-vs-leukemia after syngeneic bone marrow transplantation in mice. Leukemia Res 1996; 20: 941-946.
64. Geller RB, Esa AH, Beschorner WE et al. Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1989; 74: 1165-1171.
65. Giralt S, Weber D, Colome M et al. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 1997; 15: 667-673.
66. Byrne JL, Carter GI, Ellis I et al. Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect. Bone Marrow Transplant 1997; 20: 517-520.
67. Kwak LW, Sternas LA, Jagannath S et al. T cell responses elicited by immunization of multiple myeloma patients with idiotypic M-protein plus GM-CSF in remission after autologous transplantation. Blood 1997; 90 (Suppl. 1): 579a.